Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
30
Jul 2026
A joint research team led by Professor Daesik Kim (Department of Medicine, Sungkyunkwan University), along with Professor Yong-Sub Kim (University of Ulsan College of Medicine) and Professor Jae-Hyun Park (Sungkyunkwan University School of Medicine), has announced the development of 'OpenABE' (Open Adenine Base Editor).
30
Jul 2026
Cardiovascular disease (CVD) is among the leading causes of death worldwide. In South Korea, it is the second leading cause of death, and its incidence has continued to rise in recent years.
30
Jul 2026
When researchers screen potential tuberculosis drugs, they often end up with too many options. Some look promising but later prove to be costly dead ends.
30
Jul 2026
In a promising sign for the potential of focused sound waves to improve care for brain tumors, UVA Health researchers have determined that tumors called gliomas may be even more receptive to targeted drug delivery than normal brain tissue.